Ikena Oncology, Inc. - IKNA STOCK NEWS

BOSTON, April 28, 2022 - Ikena Oncology (Nasdaq: IKNA) announced presentations at the upcoming ASCO 2022 Annual Meeting. The company will showcase two trial-in-progress posters, detailing their clinical trials for IK-930, a TEAD inhibitor, and IK-175, an AHR antagonist. Both trials target advanced solid tumors. The presentations are scheduled for June 5, 2022, during the Poster Session on Developmental Therapeutics. Abstracts will be accessible on asco.org from May 26, 2022, at 5 PM ET.

Ikena Oncology has appointed Dr. Jotin Marango as Chief Financial Officer and Head of Corporate Development, effective April 13, 2022. With nearly 15 years of experience, Dr. Marango previously served at Aptose Biosciences as CFO and Chief Business Officer. His expertise spans oncology biopharma business, finance, and corporate relations. The appointment aligns with Ikena’s strategy to advance its targeted oncology programs and strengthen investor relations. Dr. Marango holds degrees from Harvard University and Mount Sinai School of Medicine.

Ikena Oncology, Inc. (Nasdaq: IKNA) announced its 2021 financial results, raising over $140 million in an IPO and ending the year with cash reserves of $232.2 million, ensuring its runway through mid-2024. The company advanced its clinical pipeline, initiating the Phase 1 trial for its lead candidate IK-930, a TEAD inhibitor. Additionally, IK-175, an AHR antagonist, expanded its clinical cohorts. Despite a net loss of $34.1 million in 2021, improvements in cash management and pipeline expansion position Ikena favorably for upcoming milestones in 2022.

Ikena Oncology (Nasdaq: IKNA) announced its participation in the AACR 2022 Annual Meeting, highlighting its novel TEAD inhibitor, IK-930. Dr. Jeff Ecsedy will present data supporting IK-930's clinical potential on April 11, 2022, during a minisymposium on experimental and molecular cancer therapeutics. The meeting will take place from April 8-13, 2022, in New Orleans. IK-930 targets the Hippo signaling pathway, aiming to treat cancers with mutations affecting this pathway, with ongoing Phase 1 trials for advanced solid tumors.

Ikena Oncology (Nasdaq: IKNA) will participate in the Targeted Oncology Panel at the Cowen & Co 42nd Annual Health Care Conference scheduled for March 7-9, 2022.

CEO Mark Manfredi will speak on March 8 at 9:10 a.m. ET.

The event will be streamed live and archived for 30 days. Ikena focuses on developing therapies targeting cancer pathways, with its lead program IK-930 being a TEAD inhibitor for the Hippo pathway, among others.

For more details, visit www.ikenaoncology.com.

Ikena Oncology, Inc. (Nasdaq: IKNA) announced the appointment of Richard Wooster, Ph.D., to its Board of Directors. With over 30 years of experience in oncology drug discovery, Dr. Wooster will support Ikena's targeted oncology programs aimed at difficult-to-treat cancers. His extensive background includes leading oncology programs at Translate Bio and GlaxoSmithKline, as well as significant academic contributions, including discovering the BRCA2 gene. Dr. Wooster expressed excitement about joining Ikena, especially as the company progresses with its lead candidate IK-930, targeting cancer resistance pathways.

Ikena Oncology (Nasdaq: IKNA) announced the promotion of Michelle Zhang, Ph.D., to Chief Scientific Officer (CSO) as of late November 2021. Dr. Zhang, who has over 20 years of experience in oncology drug discovery, previously served as Senior Vice President of Translational Research. Jeffrey Ecsedy, Ph.D., has assumed the newly created role of Chief Development Officer (CDO), focusing on Ikena's expanding clinical pipeline. These leadership changes aim to enhance the company's research strategy and development capabilities as it works to deliver innovative cancer therapies.

Ikena Oncology announced data from the IK-175 clinical trial during the SITC 36th Annual Meeting. The trial investigates IK-175, an oral AHR antagonist, in urothelial carcinoma patients. The ongoing Phase 1a/b study aims to assess safety and tolerability of IK-175 alone and with nivolumab. Key findings indicate a prevalent AHR signaling in urothelial carcinoma, suggesting its role in tumor progression. The clinical trial is actively recruiting and is a collaboration with Bristol Myers Squibb, focusing on biomarker-driven patient selection.

Ikena Oncology (Nasdaq: IKNA) announced that the FDA accepted its IND application for IK-930, a TEAD inhibitor targeting the Hippo pathway, with a Phase 1 clinical trial anticipated to start in early 2022. The company reported a net loss of $14.5 million for Q3 2021, up from $6.2 million a year earlier, with operational cash assets of $245.9 million expected to sustain operations through 2023. Ikena is also advancing multiple candidates targeting the RAS pathway, with several expected to emerge in the next 18 months.